Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
Trial Results • Phase 1/2Updated clinical data release Tue, May 26, 2026, 7:00 AM EDT
Company profile
Corbus Pharmaceuticals Holdings, Inc.
Pipeline2 assets
- CRB-701CRB-701 / Nectin-4 / antibody-drug conjugate / OncologyNectin-4 expressing solid tumorsPhase 3 pendingCSPC China: Phase 3 in cervical cancer milestoneChinaHNSCCPhase 1 in progressDose optimization; FDA Fast Track DesignationUSEuropeCervical cancerPhase 1 in progressDose optimization; FDA Fast Track DesignationUSEurope
- CRB-913CRB-913 / CB1R / peripherally restricted oral CB1 inverse agonist / Obesity/metabolic diseaseObesity and related conditionsPhase 1 in progress12-week dose-range study in obesity planned mid-2026
Latest news15 items
All newsCorbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
Results Call • Phase 1/2Results call Tue, May 26, 2026, 8:00 AM EDT
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Presentation / Abstract • Phase 1/2ASCO presentation Fri, May 29, 2026
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
Enrollment • Phase 1ASCO presentation Tue, May 12, 2026
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
Presentation / Abstract • Phase 1/2
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
Presentation / Abstract • Phase 1/2
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
Presentation / Abstract • Phase 1/2